Nebulized voriconazole in infections with Scedosporium apiospermum — Case report and review of the literature

• Published in: Journal of cystic fibrosis Vol. 13; no. 4; pp. 400 - 402
• Main Authors: Holle, J, Leichsenring, M, Meissner, P.E
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2014
• Subjects: Administration, Inhalation; Adolescent; Antifungal Agents - administration & dosage; Antimycotic treatment; Bronchoalveolar Lavage Fluid - microbiology; Cystic fibrosis; Cystic Fibrosis - complications; Cystic Fibrosis - diagnosis; Cystic Fibrosis - drug therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Follow-Up Studies; Fungal infections; Humans; Immunocompromised Host; Lung Diseases, Fungal - complications; Lung Diseases, Fungal - diagnosis; Lung Diseases, Fungal - drug therapy; Male; Nebulizers and Vaporizers; Pulmonary/Respiratory; Scedosporium - isolation & purification; Scedosporium apiospermum; Tomography, X-Ray Computed; Voriconazole - administration & dosage; Scedosporium apiospermum; Cystic fibrosis; Fungal infections; Antimycotic treatment
• ISSN: 1569-1993; 1873-5010
• DOI: 10.1016/j.jcf.2013.10.014

Abstract Scedosporium infections are rare complications in immunocompromised patients or patients with chronic pulmonary disease. While Scedosporium prolificans is resistant to most antimycotics, Scedosporium apiospermum is usually sensitive to voriconazole and posaconazole. Pharmacokinetics and efficacy of nebulized voriconazole have been described in a murine model previously. We report for the first time the safe and effective use of nebulized voriconazole for the treatment of severe pulmonary infection with Scedosporium apiospermum in an adolescent with cystic fribrosis.